New Zealand standardised oral formulation batch sheet

Clozapine suspension 20 mg/mL (100 mL) *

*** There is a fully funded commercial product available (Clopine® 50 mg/mL) which should be used where possible**

Patient's name		**Storage condition**	**In a refrigerator**	**At room temperature**
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	No data	30 days
Batch number		Recommended storage	-	☑

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Clozapine 100 mg tablets (Clozaril® brand)	Novartis			20 tablets			
Ora-Blend®	Perrigo			to 100 mL			
OR							
Ora-Plus®	Perrigo			50 mL			
Ora-Sweet®	Perrigo			50 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted?	Yes
Calculations performed by	
Calculations checked by (pharmacist)	
Area cleared for processing by	

Instructions to compound suspension:

Note: this formula is specific to the **Clozaril**® brand of clozapine 100 mg tablets.

1. **If Ora-Blend® unavailable**: Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
2. Crush tablets in mortar to a fine powder.
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.
5. Make up to the final volume and mix well.
6. Label and package product appropriately.

Labels	
Attach product label and auxiliary labels:	Label checked by

New Zealand standardised oral formulation batch sheet

Clozapine suspension 20 mg/mL (100 mL) *

*** There is a fully funded commercial product available (Clopine® 50 mg/mL) which should be used where possible**

Final yield	_____ mL	Checked by	
Final appearance of product	Pale white suspension.		
Container	Amber plastic mission bottle.		
Compounded by	*Name:*	*Signature:*	*Date:*
Final check and product release	*Name:*	*Signature:*	*Date:*

Special instructions:

1. A subsidised 50 mg/mL oral liquid is available and should be used whenever possible. This is a different strength to the compounded preparation. Ensure there is no potential for confusion with these different strengths if patients are switching between preparations.
2. Store at room temperature.
3. Shake well before use.

References:

1. Walker SE, Baker D, Law S. *Can J Hosp Pharm*, 2005; **58**(5).
2. Allen LV, Jr. *Secundum Artem*, 2010; **16**(1).

Prepared by	New Zealand Compounding Working Group		
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	3.0	Version approval date	15/08/19
Document review due	01/09/21		

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.